Clinical Trials Logo

Clinical Trial Summary

This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05181488
Study type Interventional
Source Gangnam Severance Hospital
Contact Yona Cho
Phone 82-2-2019-4601
Email [email protected]
Status Recruiting
Phase Phase 2
Start date April 2, 2020
Completion date April 1, 2026

See also
  Status Clinical Trial Phase
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02243007 - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT01694589 - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase 0
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Completed NCT01298011 - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Phase 2
Recruiting NCT04810910 - Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Phase 1
Completed NCT01992705 - Borderline Pancreas Study: FOLFIRINOX +SBRT Early Phase 1
Active, not recruiting NCT02047513 - Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Phase 2
Completed NCT02115022 - EUS vs. MDCT in Pancreatic Malignancy
Recruiting NCT03492671 - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Phase 2
Recruiting NCT04737551 - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting NCT03822936 - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Phase 2
Recruiting NCT03435536 - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer N/A
Recruiting NCT04472910 - GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma N/A
Withdrawn NCT03392571 - Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02775695 - Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT03718650 - Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer Early Phase 1